On May 12, 2022, Biophytis S.A. issued a press release announcing its participation at the Bio International Convention in San Diego from the 13th to the 16th of June
April 21, 2022
20-F
Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934
For The Fiscal Year Ended December 31, 2021
April 19, 2022
6-K
On April 19, 2022, Biophytis S.A. issued a press release announcing that the company will present Sarconeos (Bio101) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston, April 20-22, 2022
April 7, 2022
6-K
On April 7, 2022, Biophytis S.A. issued a press release announcing 2021 Operational and Financial Results and Gives Updates on 2022 Perspectives
April 5, 2022
6-K
On April 5, 2022, Biophytis S.A. issued a press release announcing the appointment of Philippe Rousseau as Chief Financial Officer
March 16, 2022
6-K
On March 16, 2022, Biophytis S.A. issued a press release announcing that the company will participate in a key conference on mobility for the elderly
February 4, 2022
6-K
On February 3, 2022, Biophytis S.A. issued a press release announcing that the company received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program
December 23, 2021
6-K
On December 22, 2021, Biophytis S.A. issued a press release announcing the drawing of the last tranche of ORNANE under the 2020 Atlas contract for 3 million.
December 17, 2021
6-K
On December 16, 2021, Biophytis S.A. issued a press release announcing that the company is to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3
November 23, 2021
6-K
On November 22, 2021, Biophytis S.A. issued a press release announcing the obtaining of a new 10M€ loan structure with Kreos Capital
November 15, 2021
6-K
On November 15, 2021, Biophytis S.A. issued a press release announcing US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (BIO101) in COVID 19
October 29, 2021
6-K
On October 29, 2021, Biophytis S.A. issued a press release reporting Restated Financial Statements for Previous Periods and as of June 30, 2021.
October 29, 2021
20-F
Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934
For The Fiscal Year Ended December 31, 2020
October 29, 2021
6-K
On October 28, 2021, Biophytis S.A. (the “Company” issued its Interim Financial Report for the first half of fiscal year 2021.
October 06, 2021
6-K
Biophytis S.A. issued a press release announcing it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia
October 05, 2021
6-K
On October 4, 2021, Biophytis S.A. issued a press release announcing the drawing of 2 new tranches of ORNANE under the 2020 Atlas contract for € 6 million
October 04, 2021
6-K
Biophytis announces promising full results from the SARA-INT Phase 2b trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR)
September 29 – October 2, 2021
September 30, 2021
6-K
Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29–October 2, 2021
September 17, 2021
6-K
Biophytis reports H1 2021 financial results and provides business update
September 15, 2021
6-K
Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19
June 30, 2021
6-K
Biophytis announces that the results of SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be released by August 2021
June 30, 2021
6-K
Biophytis announces that it will secure the manufacturing of Sarconeos (BIO101) for COVID-19 with a global CDMO and the next milestones for the COVA Phase 2-3 study
June 18, 2021
6-K
Biophytis announces new convertible bonds financing upt to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
May 12, 2021
6-K
Biophytis Completed the Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis
May 11, 2021
6-K
Results of the Combined General Meeting on May 10, 2021
April 30, 2021
6-K
Biophytis Second Combined General Meeting to take place on May 10, 2021 without the physical presence of its shareholers
April 29, 2021
6-K
Biophytis Receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD
April 27, 2021
6-K
Convening of another Combined General Meeting at a later date
April 26, 2021
6-K
Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021
March 22, 2021
6-K
Biophytis gives update on its Phase 2-3 COVA study on COVID-19
March 19, 2021
6-K
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd
March 12, 2021
6-K
Annual General Meeting will take place on April 26, 2021
March 11, 2021
20-F
Annual Report for the Fiscal Year Ended Dec 31, 2020
Feb 26, 2021
6-K
Biophytis Reports 2020 Full Year Results
Feb 17, 2021
6-K
Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial
Feb 16, 2021
6-K
Report of Foreign Private Issuer
Feb 9, 2021
Final Prospectus
Feb 9, 2021
F-1
Amendment No 3
Feb 8, 2021
FWP
Free Writing Prospectus
Feb 4, 2021
F-8A
For Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g)
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok